BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations

Modern Pathology

Volumn 28, Issue 8, 2015, Pages 1043-1057

  Cigognetti, Marta ^a   Lonardi, Silvia ^a   Fisogni, Simona ^a   Balzarini, Piera ^a   Pellegrini, Vilma ^a   Tironi, Andrea ^a   Bercich, Luisa ^a   Bugatti, Mattia ^a   Rossi, Giulio ^b   Murer, Bruno ^c   Barbareschi, Mattia ^d   Giuliani, Silvia ^d   Cavazza, Alberto ^e   Marchetti, Gianpietro ^f   Vermi, William ^a   Facchetti, Fabio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c OSPEDALE DELL'ANGELO   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; CELL DIFFERENTIATION; DOWN REGULATION; ENZYMOLOGY; EPITHELIUM; EVALUATION STUDY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HOMOZYGOTE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; DOWN-REGULATION; EPITHELIUM; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84938424103     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.65     Document Type: Article

References (76)

1. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-112.
2. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008;9:147-157.
3. Surveillance, Epidemiology, and End Results Program. In: NCI (http://seer.cancer.gov/) 2015.
4. Marinaccio A, Binazzi A, Branchi C et al. Registro Nazionale dei Mesoteliomi. Quarto Rapporto. Istituto Nazionale per l'Assicurazione contro gli Infortuni sul Lavoro: Roma2012.
5. Marinaccio A, Binazzi A, Marzio DD et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer 2012;130:2146-2154.
6. Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.
7. Marinaccio A, Montanaro F, Mastrantonio M et al. Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer 2005;115:142-147.
8. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
9. Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol 2013;44:1-19.
10. Churg A, Cagle P, Roggli VL. Separation of benign and malignant mesothelial proliferations. In: Silverberg SG (ed). Tumors of the Serosal Membranes, 4th edn. Vol. 3. The American Registry of Pathology: Washington, DC, 2006, pp 83-101.
11. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2012;136:1217-1226.
12. Henderson DW, Reid G, Kao SC et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohisto-chemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847-853.
13. Cury PM, Butcher DN, Corrin B et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyper-plasia and reactive pleural fibrosis. J Pathol 1999;189: 251-257.
14. Roberts F, Harper CM, Downie I et al. Immunohisto-chemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262.
15. Attanoos RL, Griffin A, Gibbs AR. The use of immuno-histochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-238.
16. Minato H, Kurose N, Fukushima M et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol 2014;141:85-93.
17. Ramael M, Lemmens G, Eerdekens C et al. Immunor-eactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;168: 371-375.
18. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992;168:377-381.
19. Cagle PT, Brown RW, Lebovitz RM. p53 immunostain-ing in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994;25:443-448.
20. Shi M, Fraire AE, Chu P et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011;35:878-882.
21. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol 2013;37:421-426.
22. Kato Y, Tsuta K, Seki K et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-220.
23. Monaco SE, Shuai Y, Bansal M et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011;135:619-627.
24. Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012;136:804-809.
25. Mogi A, Koga K, Aoki M et al. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Virchows Arch 2013;462:83-93.
26. Husain AN, Mirza MK, Gibbs A et al. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study. Lung Cancer 2014;83:324-328.
27. Pinheiro C, Longatto-Filho A, Soares TR et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol 2012;40:478-483.
28. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
29. Aerts JG, Delahaye M, van der Kwast TH et al. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol 2006;34:523-527.
30. Shen J, Pinkus GS, Deshpande V et al. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009;131:516-523.
31. Hasteh F, Lin GY, Weidner N et al. The use of immunohistochemistry to distinguish reactive meso-thelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010;118:90-96.
32. Sato A, Torii I, Okamura Y et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 2010;23:1458-1466.
33. Ikeda K, Tate G, Suzuki T et al. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010;41:745-750.
34. Ikeda K, Tate G, Suzuki T et al. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol 2011;39:395-401.
35. Su XY, Li GD, Liu WP et al. Cytological differential diagnosis among adenocarcinoma, epithelial meso-thelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Diagn Cytopathol 2011;39:900-908.
36. Mayall F, Heryet A, Manga D et al. p53 immunostain-ing is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997;8:9-12.
37. Chiosea S, Krasinskas A, Cagle PT et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-747.
38. Takeda M, Kasai T, Enomoto Y et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 2010;60:395-399.
39. Sheffield BS, Hwang HC, Lee AF et al. BAP1 immuno-histochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol; advance online publication, 28 January 2015 (e-pub ahead of print).
40. Carbone M, Ferris LK, Baumann F et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179.
41. Jensen DE, Proctor M, Marquis ST et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-1112.
42. Ventii KH, Devi NS, Friedrich KL et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-6962.
43. Nishikawa H, Wu W, Koike A et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING hetero-dimer activity. Cancer Res 2009;69:111-119.
44. Shen SX, Weaver Z, Xu X et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998;17:3115-3124.
45. Yu H, Pak H, Hammond-Martel I et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 2014;111: 285-290.
46. Ismail IH, Davidson R, Gagne JP et al. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 2014;74:4282-4294.
47. Machida YJ, Machida Y, Vashisht AA et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009;284: 34179-34188.
48. Yu H, Mashtalir N, Daou S et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010;30:5071-5085.
49. Carbone M, Yang H, Pass HI et al. BAP1 and cancer. Nat Rev Cancer 2013;13:153-159.
50. Harbour JW, Onken MD, Roberson ED et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-1413.
51. Joseph RW, Kapur P, Serie DJ et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014;120:1059-1067.
52. Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-1021.
53. Wiesner T, Murali R, Fried I et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012;36:818-830.
54. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-672.
55. Yoshikawa Y, Sato A, Tsujimura T et al. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 2011;39: 1365-1374.
56. Yoshikawa Y, Sato A, Tsujimura T et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103:868-874.
57. Arzt L, Quehenberger F, Halbwedl I et al. BAP1 protein is a progression factor in malignant pleural meso-thelioma. Pathol Oncol Res 2013;20:145-151.
58. Nasu M, Emi M, Pastorino S et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015;10:565-576.
59. Facchetti F, Lonardi S, Gentili F et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451: 669-680.
60. Vermi W, Lonardi S, Morassi M et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 2009;214: 877-886.
61. Henderson DW, Reid G, Kao SC et al. Challenges and controversies in the diagnosis of malignant mesothe-lioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 2013;66:854-861.
62. King JE, Thatcher N, Pickering CA et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopatho-logy 2006;48:223-232.
63. Hwang H, Tse C, Rodriguez S et al. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Pathol 2014;38:681-688.
64. Churg A, Cagle P, Roggli VL. Cytology of the serosal surfaces. In: Silverberg SG (ed). Tumors of the Serosal Membranes, 4th edn. Vol. 3. The American Registry of Pathology: Washington: Washington, DC, 2006, pp 11-31.
65. Husain AN, Colby T, Ordonez N et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013;137:647-667.
66. Guo G, Chmielecki J, Goparaju C et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264-269.
67. Attanoos RL, Dojcinov SD, Webb R et al. Anti-meso-thelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37:224-231.
68. Lucas DR, Pass HI, Madan SK et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003;42:270-279.
69. Takeshima Y, Amatya VJ, Kushitani K et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcoma-toid carcinoma. Histopathology 2009;54:667-676.
70. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med 2010;134:1645-1658.
71. Klebe S, Brownlee NA, Mahar A et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 2010;23:470-479.
72. Sun X, Wei L, Liden J et al. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 2005;207: 91-101.
73. Roggli V, Churg A, Chirieac LR et al. Sarcomatoid, desmoplastic, and biphasic mesothelioma. In: Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG (eds). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. IV edn. IARC Press: Lyon, 2015, pp 165-168.
74. de Reynies A, Jaurand MC, Renier A et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 2014;20:1323-1334.
75. Xu J, Kadariya Y, Cheung M et al. Germline mutation of bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 2014;74:4388-4397.
76. Cao C, Yan TD, Deraco M et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494-1498.